Contact

It's the GeneMedi's summary page for Target/Biomarker Introduction of TRAIL-R2,TNFRSF10B. The page also collects GeneMedi's different modalities and formats products for TRAIL-R2 in therapeutics/drug discovery and IVD diagnostics, which is including antibody, ADC, bispecific, antigen, ORF vector, VLP, etc. With GeneMedi's target-insight database-GM ITD database, the TRAIL-R2 target is also connected to human indications/diseases/conditions/MOA.

Target sublocation: Transmembrane Protein.

The protein encoded by this gene is a member of the TNF-receptor superfamily, and contains an intracellular death domain. This receptor can be activated by tumor necrosis factor-related apoptosis inducing ligand (TNFSF10/TRAIL/APO-2L), and transduces an apoptosis signal. Studies with FADD-deficient mice suggested that FADD, a death domain containing adaptor protein, is required for the apoptosis mediated by this protein. Two transcript variants encoding different isoforms and one non-coding transcript have been found for this gene. [provided by RefSeq, Mar 2009]

Target IDGM-T70067
Target NameTRAIL-R2
Gene ID8795
Gene Official NameTNFRSF10B
Gene AliasCD262, DR5, KILLER, KILLER/DR5, TRAIL-R2, TRAILR2, TRICK2, TRICK2A, TRICK2B, TRICKB, ZTNFR9
Protein Sub-locationTransmembrane Protein
CategoryTherapeutics Target, INN Index, Cytokine Target, Immuno-oncology Target


Pre-made TRAIL-R2-specific INN-index biosimilar (antibody&conjugates)-Conatumumab, Tilogotamab, eftozanermin alfa, Drozitumab, Tigatuzumab, Benufutamab, Lexatumumab

Anti-TRAIL-R2 therapeutic INN-index antibodies and conjugates are biosimilars expressed by mammalian cell line as a benchmark reference therapeutic antibody for drug discovery, target MOA research, cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Cat No.Products Name (INN Index)INN Name Previous Name Target FormatOrder
GMP-Bios-ab-117Pre-Made Conatumumab biosimilar, Whole mAb, Anti-TNFRSF10B/TRAIL-R2 Antibody: Anti-DR5/CD262/KILLER/TRICK2/TRICKB/ZTNFR9/TRAILR2/TRICK2A/TRICK2B/KILLER/DR5 therapeutic antibodyConatumumabTNFRSF10B/TRAIL-R2Whole mAbINN mab
GMP-Bios-ab-574Pre-Made Tilogotamab biosimilar, Whole mAb, Anti-TNFRSF10B/TRAIL-R2 Antibody: Anti-DR5/CD262/KILLER/TRICK2/TRICKB/ZTNFR9/TRAILR2/TRICK2A/TRICK2B/KILLER/DR5 therapeutic antibodyTilogotamabTNFRSF10B/TRAIL-R2Whole mAbINN mab
GMP-Bios-INN-829Pre-Made Eftozanermin Alfa Biosimilar, Fusion Protein targeting TNFRSF10B/TRAIL-R2 fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting CD262/DR5/KILLER/KILLER/DR5/TRICK2/TRICK2A/TRICK2B/TRICKB/ZTNFR9eftozanermin alfaTNFRSF10B/TRAIL-R2Fusion ProteinINN mab
GMP-Bios-ab-156Pre-Made Drozitumab biosimilar, Whole mAb, Anti-TNFRSF10B/TRAIL-R2 Antibody: Anti-DR5/CD262/KILLER/TRICK2/TRICKB/ZTNFR9/TRAILR2/TRICK2A/TRICK2B/KILLER/DR5 therapeutic antibodyDrozitumabTNFRSF10B/TRAIL-R2Whole mAbINN mab
GMP-Bios-ab-571Pre-Made Tigatuzumab biosimilar, Whole mAb, Anti-TNFRSF10B/TRAIL-R2 Antibody: Anti-DR5/CD262/KILLER/TRICK2/TRICKB/ZTNFR9/TRAILR2/TRICK2A/TRICK2B/KILLER/DR5 therapeutic antibodyTigatuzumabTNFRSF10B/TRAIL-R2Whole mAbINN mab
GMP-Bios-ab-060Pre-Made Benufutamab biosimilar, Whole mAb, Anti-TNFRSF10B/TRAIL-R2 Antibody: Anti-DR5/CD262/KILLER/TRICK2/TRICKB/ZTNFR9/TRAILR2/TRICK2A/TRICK2B/KILLER/DR5 therapeutic antibodyBenufutamabTNFRSF10B/TRAIL-R2Whole mAbINN mab
GMP-Bios-ab-309Pre-Made Lexatumumab biosimilar, Whole mAb, Anti-TNFRSF10B/TRAIL-R2 Antibody: Anti-DR5/CD262/KILLER/TRICK2/TRICKB/ZTNFR9/TRAILR2/TRICK2A/TRICK2B/KILLER/DR5 therapeutic antibodyLexatumumabTNFRSF10B/TRAIL-R2Whole mAbINN mab



Pre-made anti-TRAIL-R2 inhibitory monoclonal antibody(mab, blocking antibody inhibitor)-benchmark reference antibody for drug discovery and mechanism of action (MOA) research

Pre-made anti-TRAIL-R2 benchmark inhibitory monoclonal antibody(mab, blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). The anti-TRAIL-R2 mab is expressed and produced by mammalian cell line as a benchmark reference therapeutic antibody for biological drug discovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Cat No.Antibody NameFormatClassified by tagOrder
GM-Tg-hg-T70067-AbAnti-TRAIL-R2/TNFRSF10B monoclonal antibodymabBiofunctional antibody, Therapeutics Target antibody, Cytokine antibodymonoclonal antibody.




GENEMEDI
6th Floor, Building No.2, Kangxin Road 3377, Shanghai, China
Email: [email protected]   [email protected]
Telephone: +86-21-50478399   Fax: 86-21-50478399
Privacy Policy
Chinese Website

Apply for
Free
Sample

Sample FOC application

×